Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE semaglutide study in early Alzheimer's disease
NL-OMON61153Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in Alzheimer's disease (AD), mild cognitive impairment due to Alzheimer's disease, sponsored by Novo Nordisk. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NL-OMON61153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61153.